Liraglutide-induced acute kidney injury

Pharmacotherapy

Volumn 32, Issue 1, 2012, Pages

  Kaakeh, Yaman ^a   Kanjee, Sanna ^a   Boone, Kevin ^b   Sutton, James ^b  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

Acute kidney injury; Acute renal failure; Acute tubular necrosis; Adverse event; Exenatide; Liraglutide

Indexed keywords

LIRAGLUTIDE; PREDNISONE;

ABNORMAL LABORATORY RESULT; ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; FEMALE; FLUID THERAPY; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LABORATORY TEST; NAUSEA; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; SARCOIDOSIS; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; VOMITING;

ACUTE KIDNEY INJURY; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MIDDLE AGED;

EID: 84860780045     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/PHAR.1014     Document Type: Article

References (11)

1. Amylin Pharmaceuticals. Byetta (exenatide) package insert. San Diego, CA: 2010.
2. U.S. Food and Drug Administration. Information for healthcare professionals; reports of altered kidney function in patients using exenatide (marketed as Byetta). Available from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformation forPatientsandProviders/ucm113705.htm. Accessed July 19, 2011.
3. Novo Nordisk. Victoza (liraglutide) package insert. Princeton, NJ: 2010.
4. Jones R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. Int J Clin Prac 2010;64:1402-14.
5. Weise WJ, Sivanandy MS, Block CA, Comi RJ. Exenatide-associated ischemic renal failure. Diabetes Care 2009;32:22-3.
6. Lopez-Ruiz A, Meoro-Aviles A, Soriano-Palao J, et al. Acute renal failure when exenatide is coadministered with diuretics and angiotensin II blockers. Pharm World Sci 2010;32:559-61.
7. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009;68:898-905.
8. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. (Pubitemid 12149145)
9. Gill N, Nally JV, Fatica RA. Renal failure secondary to acute tubular necrosis. Chest 2005;128:2847-63.
10. Anderson SL, Trujillo JM. Association of pancreatitis with glucagon- like peptide-1 agonist use. Ann Pharmacother 2010;44:904-9.
11. Lee PH, Stockton MD, Franks AS. Acute pancreatitis associated with liraglutide [case report]. Ann Pharmacother 2011;45:e22.